SCHEMBL24448306

SCHEMBL24448306

Cc1ccc(NC(=O)c2ccccc2C)c(NC(=O)c2ccccc2C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.63
KMT2A Q03164 2/20 0.63
LMNA P02545 2/20 0.63
HSD17B10 Q99714 2/20 0.63
TSHR P16473 1/20 0.63
ALDH1A1 P00352 3/20 0.58
MEN1 O00255 1/20 0.58
MAPT P10636 1/20 0.58
PKM P14618 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
HPGD P15428 3/20 0.57
KCNMA1 Q12791 2/20 0.56
KCNK3 O14649 1/20 0.55
KCNK9 Q9NPC2 1/20 0.55
CSF1R P07333 1/20 0.54
GAA P10253 1/20 0.54
KDM4E B2RXH2 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13581610 0.90 MAPT (0.71) RAB9AKMT2ALMNAHSD17B10TSHR
SCHEMBL24170602 0.82 RAB9A (0.60) RAB9AKMT2ALMNAHSD17B10TSHR
SCHEMBL533731 0.81 KMT2A (0.53) RAB9AKMT2ALMNAHSD17B10TSHR
SCHEMBL3690385 0.80 HPGD (0.77) RAB9ALMNAHSD17B10TSHRALDH1A1
SCHEMBL16317646 0.79 KCNMA1 (0.76) RAB9AKMT2AALDH1A1MEN1MAPT
SCHEMBL23367899 0.79 HPGD (0.61) RAB9AKMT2ALMNAHSD17B10TSHR
SCHEMBL27970823 0.78 HPGD (0.64) RAB9AKMT2ALMNAHSD17B10ALDH1A1
SCHEMBL11400333 0.78 LMNA (1.00) RAB9AKMT2ALMNAHSD17B10TSHR
SCHEMBL14355330 0.78 ALDH1A1 (0.57) KMT2ALMNAHSD17B10ALDH1A1MEN1
SCHEMBL31642632 0.78 MAPT (0.72) RAB9AKMT2ALMNAHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES CORNELL UNIVERSITY 2022-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES PTGES, PTGS1, PTGES2 RAB9A 3843/4885KMT2A 4281/4885LMNA 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.